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e under theAbstract Investigation of the prevalence and risk factors of human papillomavirus
(HPV) infection is the basis for developing prophylactic strategies against cervical
cancer, especially for young women. This study aimed to assess the prevalence
and risk factors of HPV infection among a cohort of sexually active young French
women eligible for catch-up vaccination. Between 1997 and 2007, 2163 women aged
15–23 years attending consultations at the department of gynecology in the Hospital
of Besanc¸on (France) were screened for high risk HPV (HR HPV) infection. Risk fac-
tors were investigated through a questionnaire sent to all participants in 2010. HPV
DNA was detected by HC2 and Probe Set assays. The overall prevalence for HR HPV
and HPV16, 18 and/or HPV45 was 44.6% (95% CI, 42.5–46.7%) and 19% (95% CI, 17.3–
20.7%), respectively. The response rate to the questionnaire was 22.6%. The preva-
lence of independent risk factors (age older than 19, smoking, and oral contracep-
tion) for HPV 16/18/45 infection in this population was less than 20%. Based on this
study, HPV vaccination should be offered not only to teenage girls, but also to young
women, regardless of their sexual activity.
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Human papillomavirus (HPV) infection is the most
common sexually transmitted infection around the
world [1,2]. A large majority of women are usually
infected soon after they become sexually active in
their teens or early twenties [3,4]. Most infectionsabia. Published by Elsevier Ltd.
creativecommons.org/licenses/by-nc-nd/4.0/).
36 A. Baudu et al.are cleared within two to 3 years [5], but women
with persistent infection are at high risk of develop-
ing high-grade cervical intraepithelial neoplasia and
invasive cancer years later [6]. The main risk factor
for cervical cancers is high-risk HPV (HR HPV). Of
these viruses, HPV types 16 and 18 are responsible
for up to 70% of cervical cancers worldwide [1]. Dif-
ferent co-factors play a role in the persistence of
HPV and the risk of development and progression
of cervical lesions [7]. They are related to the host
(hormones, genetic, immune response) [8], the virus
(genotype, multiple infection, viral load and inte-
gration) [7] and the environment (high parity and
long-term oral contraceptive use [9,10], tobacco
smoking and co-infection with other sexually trans-
mitted diseases [11]). However, the key risk factor
is sexual behavior especially age at first intercourse
and number of life-time partners which reflects
exposure to HPV [12,13]. Since 2006, two vaccines
have been approved and designed to protect against
cervical intraepithelial neoplasia (CIN) grades 2 and
3 and cancers related to HPV 16 andHPV 18 infection
in women with no evidence of previous exposure to
vaccine-specific HPV types [14]. Until 2013, the
Frenchhealth authorities recommended vaccinating
14-year-old girls before their first sexual inter-
course, and proposed a catch-up vaccination for
15- to 23-year-old women only if they have not yet
had any sexual activity, or during the first year fol-
lowing their first sexual intercourse [15,16]. In
France, there are consistent data documenting
HPV prevalence in cervical lesions in women aged
over 18 [17], but data from the specific population
targeted by the vaccines are scarce [18]. Monitoring
HR HPV infections in young women prior to vaccina-
tion is necessary to detect early changes in HPV
prevalence in vaccine era and to adjust the cervical
cancer screening policies.
To give an accurate description of HPV circula-
tion in women who met the criteria of French
recommendations for vaccination until December
2012, the prevalence of HPV types 16, 18 and/or
45 was estimated in a cohort of unvaccinated
women enrolled between 1997 and 2007. The
potential risk factors related to HR HPV, and HPV
16, 18 and/or 45 infection, were also reported.
2. Methods
2.1. Patients and study design
2,163 sexually active women aged 15–23 years liv-
ing in the geographic region of Franche-Comte´,
France, who attended a consultation in the gyne-
cology department of the University Hospital of
Besanc¸on, France, between January 1, 1997 andDecember 31, 2007 were included in the study.
The Local Medical Ethics Committee (Besanc¸on,
France) and the National Committee for the pro-
tection of privacy and personal data (Commission
Nationale de lInformatique et des Liberte´s, CNIL)
approved the study. Informed consent was
obtained from all participants.
2.2. Specimen collection, cytology and HPV
testing
At the time of the gynecology consultation, all wo-
men had a pelvic examination and two cervical
smears were obtained. The first specimen was col-
lected with a Cytobrush Plus (Medscand Medical,
Malmo¨, Sweden) for conventional cytology and sent
to the pathology laboratory. Pap smear results
were reported using the Bethesda system. The
second cervical sample was collected with the
DNAPAP Cervical SamplerTM (Qiagen, Gaithersburg,
MD, USA) for HPV testing. The brush was trans-
ferred into a vial containing 1 mL Specimen Trans-
port Medium (STM) (Qiagen) and the specimen
was then processed for routine HR HPV DNA testing
with the Hybrid Capture 2 assay (HC2) (Qiagen)
according to the manufacturers instructions. This
test permits the detection of the HPV DNA of 13
HR-HPV types, namely HPV 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59 and 68. Samples were then
stored at 20 C.
All cervical specimens positive for HR HPV and
from which enough material was available were re-
tested in 2008 using the HPV 16/18/45 Probe Set
Test (Qiagen). This test is also based on liquid
hybridization with specific probes that make it pos-
sible to confirm the presence of HPV16 and/or
HPV18 and/or HPV45 DNA in the samples without
identifying the specific type. The HPV 16/18/45
Probe Set Test has an analytical sensitivity (1 pg/
mL) similar to that of the HC2 test.
2.3. Questionnaire investigating risk factors
for HPV infection
In June 2010, a questionnaire was sent with an
explanatory letter to all females enrolled in the
study between 1997 and 2007, to the postal address
indicated in their medical file. Questions were
regarding socio-demographic characteristics (edu-
cational level, smoking) at the time of HPV testing
performed between 1997 and 2007, gynecological
history (age at first HPV test, age at first menstru-
ation, age at first pregnancy, number of children at
HPV test, previous sexually transmitted diseases),
and sexual behavior (age at first intercourse, dura-
tion between age at first intercourse and age at
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lation, the CNIL authorized to ask the question
regarding the number of sexual partners at the
time of the questionnaire, but not at the time of
the HPV test. A reminder was sent by post four
weeks later if the questionnaire was not returned.
2.4. Statistical analysis
The number of females enrolled in the cohort
(n = 2,163) allowed the study team to estimate
the overall prevalence of HR HPV and HPV 16/18/
45 with a precision of 5% and 10%, respectively.
Continuous data are presented as mean (range)
and categorical (qualitative) variables as number
and percentage. A Mac Nemar test was performed
to test the association between HPV and cytology
results.
Prevalence was defined as number of women
positive for HPV infection at the time of the first
gynecology consultation between 1997 and 2007/to-
tal number of women screened by HPV test. Further
analysis was performed to verify the representative-
ness of the sample of women who responded to the
questionnaire in 2010 in comparison with the overall
cohort of women included between 1997 and 2007.
To assess the association between HPV infection
and the characteristics of women at the time of the
HPV test, a crude odds ratio (OR) with exact 95%
confidence interval (CI) was calculated. The num-
ber of subjects to be included in the risk factors
analysis was based on the detection of a minimum
OR of predictors using logistic regression. For an
OR = 1.5, with an alpha risk of 5% and a power of
80%, 450 subjects are sufficient.
Continuous variables such as age at HPV test and
the period of inclusion were categorized and tested
by theWald v2 test.When potential risk factors were
found to be associated with infection with a p value
<0.10 by univariate analysis, theywere subsequently
entered into the multivariate logistic regression
model (stepwise selection) to identify factors inde-
pendently associated with HR HPV infection or 16/
18/45 HPV infection. Goodness of fit for the final
model was assessed using the Hosmer–Lemeshow
test. The multivariate models tested were adjusted
for theperiod. All testswere two-sidedand ap-value
<0.05 was considered statistically significant. All
analyses were performed using SAS version 9.2.
(SAS Institute, Cary, NC, USA).
3. Results
From 1997 to 2007, 2163 females aged 15–23 years
who attended a consultation in the gynecology
department were enrolled in the study. Theaverage age of the cohort was 21.1 years (median:
21.4, standard error 2.0). The questionnaire inves-
tigating retrospectively the potential risk factors
was returned by 511 women, of whom 491 had
completed the questionnaire, and 20 refused to
respond (Fig. 1).
3.1. Prevalence of high risk HPV and HPV
types 16/18/45 according to age
Out of the 2163 specimens collected, 44.6% (95%
CI: 42.5–46.7%) were positive for HR HPV. The
results from ProbeSet test showed that out of the
2038 analyzable specimens, 19% (95% CI:
17.3–20.7%) were positive for HPV 16/18/45
(Table 1).
The overall prevalence by age is reported in
Table 1 and Fig. 2. There was an overall significant
increase in HR HPV prevalence with age until
22 years (29.4–49.1%, p = 0.0013, b = 2.29). Wo-
men over 20 years of age were at a significantly
higher risk of being infected by HR HPV
(p = 0.006) in comparison with women under 20
(46.4% and 39.7%, respectively). However, preva-
lence of HPV 16/18/45 showed an almost similar
age-distribution around 18%.
Of the 2,163 cervical swabs, cytology was avail-
able for 63% (1377/2163) of the samples at the
time of the study. Among those samples 68.8%
(948/1377) were within normal limits (WNL),
whereas 8.4% (116/1377) showed atypical squa-
mous cells of undetermined significance (ASCUS),
19.0% (262/1377) low-grade squamous intraepithe-
lial lesion (LSIL) and 3.7% (51/1377) high-grade
squamous intraepithelial lesion (HSIL). Over the
1377 samples, 558 (40.5%) were HR HPV-positive.
This proportion increased significantly according
to cytological diagnosis severity from 24% in normal
specimens to 59% in ASCUS, 81% in LSIL and 92% in
HSIL (p < 0.0001). Among 948 women with normal
cytology the overall HR HPV prevalence varied
according to age from 19% below 19 years to
25.2% above 19 years (p < 0.0001).
As for HPV 16/18/45, they were detected in 9.9%
of WNL samples, 25.2% of ASCUS, 33.6% of LSIL and
59.1% of HSIL.
3.2. Risk factors associated with HR HPV and
HPV 16/18/45 infection
The response rate to the questionnaire was 22.6%
and the mean age of responders was 27.3 years in
2010.
Table 2 shows the number of young women en-
rolled every year (starting from 1997) and the num-
ber of women who completed the questionnaire.
Table 1 Prevalence of HR HPV and HPV 16, 18 and/or 45.
Age Proportion in
population (%)
HR HPV positive HPV 16/18/45 positive
Sample size Prevalence (%) (95% CI) Sample size Prevalence (%) (95% CI)
[15–18] 34.81 182 35.71 (28.8–42.7) 175 16.57 (11.1–22.1)
[18–19] 12.19 178 39.33 (32.2–46.5) 170 17.06 (11.4–22.7)
[19–20] 11.76 249 43.37 (37.2–49.5) 238 15.55 (11.0–20.2)
[20–21] 10.81 330 43.94 (38.6–49.3) 307 19.54 (15.1–24.0)
[21–22] 10.19 350 46.29 (41.1–51.5) 335 22.09 (17.7–26.5)
[22–23] 10.10 436 49.08 (44.4–53.8) 405 19.75 (15.9–23.6)
[23–24] 10.10 438 45.89 (41.2–50.6) 408 19.36 (15.5–23.2)
Total 100.00 2163 44.61 (42.5–46.7) 2038a 19.04 (17.3–20.7)
a The data are based on results for 2038 women whose specimens could have been tested.
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Fig. 2 Prevalence of high risk HPV and HPV 16, 18,
and/or 45 by age. Abbreviations: HR, high risk; HPV,
human papillomavirus. Note: One age class was created
for women aged 15 and 16 years because of low number
in each group.
Fig. 1 Flow chart presenting the design of the study. 145 questionnaires could not have been sent because addresses
were not available.
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were similar at the exception for year 1998. Thus
the responder sample is representative of the en-
tire cohort. Moreover, there was no statistical dif-
ference between women who responded to the
questionnaire and those who did not respond in
terms of age at HPV test, HR HPV-positivity
(41.1% vs. 44.6%) and HPV 16, 18, and/or 45
(17.5% vs. 17.9%).
The socio-behavioral characteristics of the wo-
men who answered the questionnaire are summa-
rized in Table 3. The median ages at first
menstruation and first sexual intercourse were
12.8 and 16.5, respectively. No association was
found between the infection status (HR HPV and
HPV 16, 18 and/or 45) and the age at first menstru-
ation or at first intercourse. The average age at
first pregnancy was 20 years for responders who
had had a baby before the HPV test (n = 50).
Table 2 Response rate to the questionnaire sent to women according to the year of inclusion.
Year of inclusion
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Number of women at the time of
HPV test
27 75 114 113 94 231 300 392 307 225 285
Number of responders at survey 6 9 29 26 18 53 67 89 70 55 69
Response rate (%) 22.2 12.0 25.4 23.0 19.1 22.9 22.3 22.7 22.8 24.4 24.2
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reported taking oral contraceptives at the time of
the HPV test (55.6%), the risk of infection with
HR HPV and HPV 16/18/45 increased significantly
(OR = 1.78, 95% CI, 1.08–2.94 and OR = 1.57, 95%
CI, 1.08–2.27, respectively) compared with women
using other methods of contraception. Moreover,
249 responders (53.5%) were smokers at the time
of the HPV test, and smoking increased the risk
of HR HPV infection (OR = 1.83, 95% CI, 1.27–
2.65) and HPV 16/18/45 infection (OR = 1.78, 95%
CI, 1.09–2.91). The average age at which women
consulted the gynecologist and tested for HPV
was 21 years, with a median of 4.5 years between
the first intercourse and the first consultation in
gynecology. Women who consulted less than
4 years before their first sexual intercourse had a
lower risk of being infected by HR HPV
(OR = 0.65, 95% CI, 0.45–0.94) and HPV 16, 18
and/or 45 (OR = 0.58, 95% CI, 0.35–0.96).Table 3 Socio-behavioral characteristics among women who
Characteristics Overall Sample
Numbers of
responses
Mean (range)
or n (%)
Age at first menstruation
(years)
488 12.8 (9–19)
Age at first sexual
intercourse (years)
488 16.5 (12–22)
Age at first pregnancy
(years)
50a 20.2 (16–23)
Age at the time of HPV
test (years)
491 21.1 (15.1–23.9)
Time between first
intercourse and HPV
test (years)
488 4.5 (0–9.63)
Smoking at the time of
HPV test
465 249 (53.5%)
Use of oral contraception
at the
time of HPV test
465 259 (55.6%)
HR, high risk; HPV, human papillomavirus.
a 16 missing.The multivariate model identified two factors
that were independently associated with HR HPV
and HPV 16, 18 and/or 45 infections: smoking and
use of oral contraceptives (Table 4). Two factors
were independently associated with HR HPV infec-
tion such as the age >19 years (OR = 2.87, 95% CI,
1.40–5.83) and having a baby at the time of the
HPV test that showed a protective effect
(OR = 0.48, 95% CI, 0.24–0.95).
Due to privacy legislation, only the number of
sexual partners at the time of the questionnaire
was available. Interestingly, women who had P4
sexual lifetime partners at the survey time pre-
sented the highest rate of positivity for HRHPVwhen
included in the study for HPV testing (p < 0.0001).
4. Discussion
This is the largest French epidemiological study
that focused on sexually active women aged 15 toresponded to the questionnaire in 2010 (n = 491).
HR HPV+ HPV 16/18/45+
Numbers Mean (range)
or n (%)
Numbers Mean (range)
or n (%)
199 12.8 (9–19) 84 12.7 (9–17)
200 16.5 (12–22) 84 16.3 (13–22)
202 21.7 (16–23) 82 19 (16–22)
202 20.7 (13–23) 86 21.3 (15.4–23.9)
200 4.8 (0.5–9.6) 85 5.0 (0.5–9.6)
199 122 (61.3%) 83 53 (63.8%)
202 126 (62.3%) 86 56 (65.1%)
Table 4 Multivariate analysis of factors associated with HR HPV and HPV16, 18 and/or 45 infections among 491 sexually
active females aged 15 to <24 years.
HR HPV positive HPV 16, 18 and/or 45 positive
Characteristics N (%) OR (95% CI) p-Value N (%) OR (95% CI) p-Value
Age at the time of HPV test (years) 0.0005 0.06
[15–19] 16 (20.8) 1 [Reference] 9 (12.9) 1 [Reference]
[19–21] 61 (42.1) 2.87 (1.40–5.83) 24 (22.2) 1.54 (0.62–3.84)
[21–23] 79 (47.0) 3.83 (1.91–8.84) 39 (30.4) 2.82(1.19–6.63)
[23–24] 46 (45.5) 4.19 (1.98–8.84) 14 (20.3) 1.98 (0.75–5.20)
Smoking habit at the time
of HPV test
0.002 0.013
No 77 (35.6) 1 [Reference] 33 (17.8) 1 [Reference]
Yes 122 (48.9) 2.03 (1.36–3.05) 53 (27.9) 2.02 (1.17–3.49)
Contraception at the time
of HPV test
0.012 0.016
Pill 126 (45.8) 1.62 (1.09–2.43) 56 (27.5) 1.90 (1.10–3.28)
Other method 74 (34.2) 1 [Reference] 30 (17.5) 1 [Reference]
Having one baby at the
time of HPV test
0.032 0.60
No 179 (42.1) 1 [Reference] 73 (22.8) 1 [Reference]
Yes 15 (30.0) 0.48 (0.24–0.95) 9 (20.4) 0.83 (0.35–1.96)
Age at first menstruation (years) 0.23 0.23
<12 41 (47.1) 1.37 (0.86–2.19) 19 (29.2) 1.54 (0.85–2.82)
P12 158 (39.4) 1 [Reference] 65 (21.1) 1 [Reference]
CI: confidence interval.
Stepwise model.
Adjusted on age at first sexual intercourse (years) and duration between age at first sexual intercourse and age at HPV test (years).
Goodness of fit based on Hosmer–Lemeshow p = 0.36 for exposure to HR HPV and p = 0.54 for exposure to HPV 16, 18 and/or 45.
40 A. Baudu et al.23 years taking into account socio-behavioral char-
acteristics and risk factors of HPV infection. In this
cohort, the overall prevalence of HR HPV was
44.6%, with 19% (95% CI, 17.3–20.7%) infected with
current vaccine types 16 and/or 18. In Danish wo-
men the prevalence of HR HPV as well as HPV 16/
18/45 reached similar rates to those reported here
[19]. A Swedish study reported an even higher prev-
alence of HR HPV infection of 61.6% in a group of
sexually active women aged 15–23 with a tendency
to increase from 16 to 21 years of age [20]. The
high prevalence of HPV in this cohort also agrees
with two recent studies that included unvaccinated
young women participating in the Chlamydia tra-
chomatis screening program in England [12] and
in the Netherlands [21]. Italian studies reported
rates ranging from 10% to 15% for HPV 16 and 18
among sexually active women of 18–24 years of
age [22,23]. In contrast Dunne et al. showed a low-
er HR HPV prevalence ranging from 18% to 28%
among American sexually active females aged
14–24 years [24]. Monsonego et al. found a HR
HPV prevalence of 23.5% in women aged <25 years
attending private gynecology practices in Paris,
France [18,25], a prevalence very similar to thatobserved in German women attending a gynecolo-
gist in private practice [26]. Manhart et al., who in-
cluded both sexually active women and women
having signed a virginity pledge, found a rate of
only 7.8% [27]. Whether national and regional dif-
ferences in age and type specific patterns of HPV
prevalence may be partly attributed to the proto-
col used for specimen collection and HPV assay,
the overall high prevalence of HR HPV as well as
HPV 16/18/45 found in this series of young females
could also be explained by the hospital-based
recruitment of a high-risk population as shown by
a high percentage of abnormal cytology (31.2%)
which is in agreement with a previous observation
in another series of young women [28]. The rate
of HPV 16/18/45 in HSIL (59.1%) is similar to that
reported by Coupe´ et al. [29]. Surprisingly, in the
present report, the prevalence of the HPV was sta-
ble while it peaks at 22–24 years in a population of
Dutch women with a significant decrease with age
thereafter [29].
Teenagers who consult in STD planning or a hos-
pital have likely a higher frequency of risk factors
and a higher HPV 16 prevalence compared with pri-
mary care patients [30]. The Danish study pointed
Prevalence and risk factors of human papillomavirus infection 41out that women aged 15–22 years could also have a
greater interest in health, or a higher rate of risky
behavior [19]. Nevertheless, this cohort did not dif-
fer from the general French population in terms of
age at first menstruation (12.8 vs. 12.6) or age at
first sexual intercourse (16.5 vs. 17), but the age
at first pregnancy appeared to be lower (20.2 vs.
29.4) [31], which could be explained by socio-
demographic reasons such as income or level of
education. However, due to ethical reasons, it
was not allowed to collect these two personal data
that could not have been analyzed in the multivar-
iate model.
These results also identified well-known risk fac-
tors such as smoking habits and oral contraception
for both HR HPV and HPV 16/18/45 infection. The
International Agency for Research on Cancer HPV
Prevalence Surveys noted an increasing risk of
HPV infection with smoking intensity, after allow-
ing for the lifetime number of sexual partners
[32]. Similarly, in a cohort of 8508 women from
Costa Rica, a positive association was found be-
tween smoking and HPV infection, but only for
HPV 16 [33]. The association between smoking
and HPV infection has also been confirmed in other
studies among females aged 13–21 and 18–
20 years [34,35], whereas others did not report
any association [36,37]. The higher risk of being in-
fected by HPV among women taking an oral contra-
ceptive could be indicative of high-risk sexual
behaviors. However, it is difficult to separate the
effects of the contraceptive pill use from those
of sexual activity, and several investigations have
found no association [38,39]. Recently, a meta-
analysis confirmed that first coitus at a young age
(615), increased number of pregnancies, increased
number of sexual partners, use of contraceptives,
smoking and chewing tobacco habits, and early
age at marriage were significant risk factors for
HPV infection [40]. These results stress that fe-
males aged 19–23 who were current smokers and
taking an oral contraceptive might need closer HR
HPV follow-up than the general population. Even
risk factors for exposure to HPV infection were
investigated retrospectively in this study, some-
times up to 13 years later for women enrolled in
1997, the information collected from the question-
naire, such as age at first menstruation, first inter-
course or first child are major events in a womans
life and should not be subject to memory bias,
whereas data concerning smoking and oral contra-
ception use could be affected by memory bias.
Several international studies have confirmed
that a high number of lifetime sexual partners
increased the risk of infection with one or moreHPV types over time [12,13,18,25,26,41]. Unfortu-
nately, due to ethical reasons, data on the number
of sexual partners at the time of the HPV test were
unobtainable, and this variable could not be
studied.
Until 2013, French recommendations limited
vaccination to young women who had never had
any sexual activity or who were within 1 year of
their first sexual encounter. It is best to get the
HPV vaccine before becoming sexually active and
coming in contact with HPV. However, the vaccine
is recommended in many countries for women who
are already sexually active because they are unli-
kely to be infected by both HPV 16/18. Interest-
ingly, this study showed that HPV 16/18 and/or
45 were present in 19% of the sexually active young
women. Thus, if HPV 45 is not taken into consider-
ation, it could be estimated that the implementa-
tion of the vaccination against HPV 16 and 18
could prevent HPV 16/18 infection in more than
80% of this cohort. In the general population, the
prevalence of the vaccine HPV types is likely much
lower than among the hospital-based cohort, sug-
gesting that the young population studied would
benefit much more from prophylactic vaccination,
regardless of their sexual activity status. Indeed,
the efficacy of the quadrivalent vaccine for women
who were seropositive for HPV and DNA-negative at
the time of enrollment was at least 66.9% [42].
Several modeling studies have shown that vacci-
nation programs including 12-year-old girls and
catch-up vaccination for adolescents and young
adult women with no time restrictions after the
first sexual intercourse result in faster decreases
in HPV-related disorders [43–45]. These results
were observed at the level of the population in
Australia, where, after the start of the HPV vacci-
nation program, there was an acceleration in the
public health impact of vaccination and an increase
of the short-term benefits [46].
This study provides the first estimate of preva-
lent HPV 16/18/45 infection among a large French
cohort of young females aged 15–23 years. Fur-
thermore, the same risk factors were identified
for HR HPV and HPV 16, 18 and/or 45 infections,
such as smoking and the use of oral contraceptives.
Overall, the HR HPV prevalence was high (44.6%),
with the highest prevalence noted among females
aged 20–23 years, underlining the importance of
following up women who are HR HPV-positive and
who have not been vaccinated. However, the prev-
alence of HPV vaccine types was relatively low
suggesting that it could be possible to expand the
target group for catch-up vaccination by including
women who are already sexually active for more
42 A. Baudu et al.than one year. Given the lower than expected
coverage rate of HPV vaccine in France, vaccina-
tion advisory boards have provided recently new
recommendations.
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